用于骨髓纤维化治疗的JAK抑制剂:优势和局限性
K Thaw1, C N Harrison2, P Sriskandarajah1
1Department of Haematology, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.
Current hematologic malignancy reports
|October 14, 2024
概括
雅努斯酶抑制剂 (JAKis) 对髓纤维化患者有好处,但耐药性等挑战仍然存在. 较新的,选择性的JAKis和组合疗法显示出改善治疗结果的希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓纤维化 (MF) 治疗随着Janus激酶 (JAK) 抑制剂的开发而发展.
- JAK抑制剂向JAK2 V617F突变,这种突变是MF病变发生的核心.
研究的目的:
- 批判性地分析目前用于骨髓纤维化症的JAK抑制剂的优点和局限性.
- 审查JAK抑制剂治疗MF的最新进展.
主要方法:
- 对当前用于骨髓纤维化治疗的JAK抑制剂的文献综述.
- 对有关疗效,耐久性和耐药性模式的临床数据的分析.
主要成果:
- 雅克抑制剂改善了MF患者的症状负担,脏大小和存活率.
- 治疗耐药性和有限的反应耐久性仍然是重大挑战.
- 选择性JAK抑制剂和组合疗法的开发是新兴的战略.
结论:
- 虽然JAK抑制剂已经改变了MF护理,但挑战仍然存在.
- 优化治疗策略,包括选择性JAK抑制剂和组合疗法,为未来提供希望.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Types of Intermediate Filaments
3.6K
The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
3.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
633
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
633
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
143
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
143


